Rugosin E, an ellagitannin, inhibits MDA-MB-231 human breast cancer cell proliferation and induces apoptosis by inhibiting nuclear factor-κB signaling pathway

Cancer Letters

Volumn 248, Issue 2, 2007, Pages 280-291

  Kuo, Po Lin ^a   Hsu, Ya Ling ^a   Lin, Ta Chen ^b   Tzeng, Wen Sheng ^c   Chen, Yin Yi ^a   Lin, Chun Ching ^d  

^a CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^b CHUNGTAI INST HLTH SCI TECHNOL   (Taiwan)

^c Chi Mei Foundation Hospital   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Breast cancer; Cell cycle; NF B; Rugosin E

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CASPASE 9 INHIBITOR; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; CYTOCHROME C; ELLAGITANNIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN BCL XL; RUGOSIN E; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA BINDING; DNA TRANSCRIPTION; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MITOCHONDRION; ONCOGENE C MYC; PRIORITY JOURNAL; REPORTER GENE;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; HUMANS; HYDROLYZABLE TANNINS; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 33847253921     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.08.006     Document Type: Article

References (30)

1. Evan G.I., and Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 411 (2001) 342-343
2. Herr I., and Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood 98 (2001) 2603-2614
3. Dixit V., and Mak T.W. NF-kappaB signaling. Many roads lead to Madrid. Cell 111 (2002) 615-619
4. Karin M., Cao M.Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2 (2002) 301-310
5. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 6 (2004) 203-208
6. Shishodia S., Gutierrez A.M., Lotan R., and Aggarwal B.B. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Cancer Res. 65 (2005) 9555-9565
7. Srivastava S.K., and Singh S.V. Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappaB activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cells. Carcinogenesis 25 (2004) 1701-1709
8. Denoyelle C., Vasse M., Korner M., Mishal Z., Ganne F., Vannier J.P., Soria J., and Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22 (2001) 1139-1148
9. Hatano T., Ogawa N., Shingu T., and Okuda T. Rugosins D, E, F and G, dimeric and trimeric hydrolysable tannins with valoneoyl group(s), form flower petals of Rosa rugosa Thunb. Chem. Pharm. Bull. 38 (1990) 3341-3346
10. Teng C.M., Kang Y.F., Chang Y.L., Ko F.N., Yang S.C., and Hsu F.L. ADP-mimicking platelet aggregation caused by rugosin E, an ellagitannin isolated from Rosa rugosa Thunb. Thromb. Haemost. 77 (1997) 555-561
11. Hastak K., Gupta S., Ahmad N., Agarwal M.K., Agarwal M.L., and Mukhtar H. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 22 (2003) 4851-4859
12. Baselga J., and Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res. Treat. 29 (1994) 127-138
13. Nakshatri H., Bhat-Nakshatri P., Martin D.A., Goulet Jr. R.J., and Sledge Jr. G.W. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 17 (1997) 3629-3639
14. Loyer P., Trembley J.H., Katona R., Kidd V.J., and Lahti J.M. Role of CDK/cyclin complexes in transcription and RNA splicing. Cell. Signal. 17 (2005) 1033-1051
15. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 (1999) 1501-1512
16. Hamel P.A., and Hanley-Hyde J. G1 cyclins and control of the cell division cycle in normal and transformed cells. Cancer Invest. 15 (1997) 143-152
17. Hajra K.M., and Liu J.R. Apoptosome dysfunction in human cancer. Apoptosis 9 (2004) 691-704
18. Bhat-Nakshatri P., Sweeney C.J., and Nakshatri H. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene 21 (2002) 2066-2078
19. Matsumoto G., Namekawa J., Muta M., Nakamura T., Bando H., Tohyama K., Toi M., and Umezawa K. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin. Cancer Res. 11 (2005) 1287-1293
20. Wu J.T., and Kral J.G. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J. Surg. Res. 123 (2005) 158-169
21. Pan Q., Bao L.W., and Merajver S.D. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol. Cancer Res. 1 (2003) 701-706
22. Munster P.N., and Norton L. Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Breast Cancer Res. 3 (2001) 361-364
23. Blakely C.M., Sintasath L., D'Cruz C.M., Hahn K.T., Dugan K.D., Belka G.K., and Chodosh L.A. Developmental stage determines the effects of MYC in the mammary epithelium. Development 132 (2005) 1147-1160
24. Xie Z., Zeng X., Waldman T., and Glazer R.I. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1. Cancer Res. 63 (2003) 5370-5375
25. Watabe M., Hishikawa K., Takayanagi A., Shimizu N., and Nakaki T. Caffeic acid phenethyl ester induces apoptosis by inhibition of NFkappaB and activation of Fas in human breast cancer MCF-7 cells. J. Biol. Chem. 13 (2004) 6017-6026
26. Cai Z., Korner M., Tarantino N., and Chouaib S. IkappaB alpha overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-kappaB activation but not tumor necrosis factor-alpha-induced apoptosis. J. Biol. Chem. 272 (1997) 96-101
27. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., and Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 65 (2005) 6934-6942
28. Fahy B.N., Schlieman M.G., Mortenson M.M., Virudachalam S., and Bold R.J. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother. Pharmacol. 56 (2005) 46-54
29. Oost T.K., Sun C., Armstrong R.C., Al-Assaad A.S., Betz S.F., Deckwerth T.L., Ding H., Elmore S.W., Meadows R.P., Olejniczak E.T., Oleksijew A., Oltersdorf T., Rosenberg S.H., Shoemaker A.R., Tomaselli K.J., Zou H., and Fesik S.W. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. 47 (2004) 4417-4426
30. Aggarwal B.B., Shishodia S., Takada Y., Banerjee S., Newman R.A., Bueso-Ramos C.E., and Price J.E. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res. 11 (2005) 7490-74908